Zoetis Inc.·Healthcare

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of Zoetis Inc. (“Zoetis” or the “Company”) (NYSE: ZTS) investors concerning the Company's possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ZOETIS INC. (ZTS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@how.

Barron's Oil & Blue Chip Tips for May 2026 highlight 20 stocks, with 11 deemed 'safer' based on free cash flow yields exceeding dividend yields. Top ten by yield are projected to deliver average net gains of 36.08% by May 2027, with risk/volatility 24% below the market average. Zoetis (ZTS), Danaher (DHR), and Accenture (ACN) lead in projected returns, with ZTS estimated to net 60.33% and lower-than-market volatility.

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Zoetis Inc. (“Zoetis” or the “Company”) (NYSE: ZTS) on behalf of investors concerning the Company's possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON ZOETIS INC. (ZTS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.What Is The Investigation About?On May 7, 2026, Zoetis reported financial results for the first quarter of 2026. Among ot.

[url="]The Law Offices of Frank R. Cruz[/url] continues its investigation of Zoetis Inc. (âZoetisâ or the âCompanyâ) (NYSE: [url="]ZTS[/url]) on behalf

[url="]Glancy Prongay Wolke and Rotter LLP[/url], a leading national shareholder rights law firm, continues its investigation on behalf of Zoetis Inc. (âZoetisâ

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Zoetis Inc. (“Zoetis” or the “Company”) (NYSE: ZTS) investors concerning the Company's possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON ZOETIS INC. (ZTS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.What Happened?On May 7, 2026, Zoetis reported financial results for.
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Healthcare
Drug Manufacturers - General
13,800
2013-02-01
0.86